Printer Friendly

CAMBREX ANNOUNCES NEW BORROWING FACILITY

 CAMBREX ANNOUNCES NEW BORROWING FACILITY
 EAST RUTHERFORD, N.J., March 30 /PRNewswire/ -- Cambrex Corporation


(AMEX: CBM) announced today that it has arranged a new borrowing facility for $55 million with NBD Bank, N.A. acting as agent, to replace its current facility which would have expired in May 1992. NBD, National Westminster Bank NJ and United Jersey Bank have committed to supply the $55 million facility, and negotiations are proceeding to expand it by $10 million. The funds are to be used for current corporate needs, the acquisition of Hexcel's Fine Chemicals Business and for future investments.
 Cambrex Corporation manufactures a broad line of specialty chemicals and commodity chemical intermediates. The chemical families of castor oil, pyridine, organometallics, succinic anhydrides, organobromines, and ammonia reaction chemistry are used by the company to produce compounds for its five product categories: urethane systems and additives, coatings, health and cosmetic products, agricultural chemical intermediates, and specialty and fine chemicals.
 -0- 3/30/92
 /CONTACT: Peter Tracey, vice president and chief financial officer of Cambrex, 201-804-3010/
 (CBM) CO: Cambrex Corporation ST: New Jersey IN: CHM SU:


SH-TQ -- NY079 -- 2977 03/30/92 15:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1992
Words:190
Previous Article:MERRY LAND TO FILE REGISTRATION STATEMENT WITH SEC
Next Article:BAUM CALLS FOR LABEL DEADLINE EXTENSION
Topics:


Related Articles
CAMBREX REPORTS EARNINGS FOR FOURTH QUARTER AND YEAR
CAMBREX REPORTS IMPROVED SECOND QUARTER 1992 EARNINGS
CAMBREX REPORTS PREPAYMENT OF 9 PERCENT CONVERTIBLE SUBORDINATED NOTES
CAMBREX CORPORATION ACQUIRES NOBEL PHARMA CHEMISTRY BUSINESS
CAMBREX'S BULK ACTIVE INGREDIENTS BUSINESS TO BE EXPANDED
CAMBREX ADVANCES PHARMACEUTICAL BULK ACTIVE STRATEGY
Cambrex Corporation Reports Continued Improvement In Third Quarter Net Income
Cambrex Corporation Reports Increased Net Income in the First Quarter
Cambrex Announces New $400 Million Credit Line
Cambrex Corporation Announces R&D Charge

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters